NR
The startup develops a targeted immunotherapy using liposomes that deliver cancer treatments directly into tumors and their microenvironments while metabolizing systemic toxicity. This approach aims to enhance the efficacy of cancer therapies and minimize adverse effects associated with traditional treatment methods.
Updated 18 months ago
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SA
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a targeted immunotherapy using liposomes that deliver cancer treatments directly into tumors and their microenvironments while metabolizing systemic toxicity. This approach aims to enhance the efficacy of cancer therapies and minimize adverse effects associated with traditional treatment methods.